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ABSTRACT 
Objectives: Endometrial cancer is the most common malignant cancer of female reproductive 
organs. The number of diagnosed cases of endometrial cancer is increasing from year to year. 
Endometrial cancer is a neoplasm with a good survival rate. However, there are also cases 
with a fast, aggressive course. In recent years, the triple negative phenomenon (TNP) has been 
identified as one of the factors determining shorter survival in patients with endometrial 
cancer. 
Material and methods: The study covered 265 patients with histopathologically confirmed 
endometrial cancer. Patients were divided into two groups: 1) patients with endometrial 
cancer with TNP; 2) patients with endometrial cancer without TNP. 
Tissue microarrays (TMA) were examined with immunohistochemistry to evaluate the 
expression of estrogen, progesterone and HER2 receptors. In several cases FISH method was 
used to assess HER2. The expression was evaluated by computer image analysis using the 
Nuclear Image Analysis virtual microscopy system. The evaluation of HER2 expression was 
 
 
performed manually. The criterion for TNC diagnosis was H-Score < 50 or < 75 and Allred 
score < 4.  
Results: Depending on the scoring system used, TNP was found in from 10.19% to 15.09% 
of cases. Regardless of the criteria employed in endometrial cancer, the presence of TNP was 
neither a factor increasing the risk of death nor it affected the patients' survival.  
Conclusions: The proportion of TNP diagnosed in endometrial cancer depends on the 
examined population and the diagnostic criteria. The incidence of TNP did not affect the 
survival of patients.  
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Endometrial cancer is the most common female genital cancer in the developed 
countries [1]. According to the WHO (World Health Organization) report, the number of 
reported new cases of endometrial cancer was 327,259 in 2018, an increase of 7,659 new 
cases compared to the previous report published in 2012 [2].  
 Similarly, to the estrogen receptor (ER), the positive expression of progesterone 
receptor (PR) is associated with increased survival in endometrial carcinoma [3, 4]. In 2013, a 
multicentre study was conducted which showed reduced survival in women with endometrial 
cancer in the absence of PR and ER expression [5]. The lack of PR expression is also 
associated with a higher risk of relapse of the neoplastic process [6]. The degree of ER 
expression is considered as an independent prognostic factor. Reduced survival in endometrial 
cancer patients occurred in the absence of ERα expression [7]. Patients showing no ERα 
expression were diagnosed with higher neoplastic grading and higher stage of neoplastic 
progression [8].  
 The amplification of the HER2 gene, which results in an increased amount of HER2 
protein, is characteristic of the second type of endometrial cancer, the so called non-estrogen-
dependent endometrial cancer. This concerns about 17–30% of cases [9]. It was found that 
 
 
endometrial cancers with positive expression of HER2 receptor have a more aggressive 
clinical course [10]. Although HER2 gene amplification is characteristic for type II 
endometrial cancers, some authors confirm the fact that HER2 positive expression is a 
prognostic factor for type I endometrial cancers [11, 12].  
The triple negative phenomenon (TNP) was first described in association with breast 
cancer. TNP means the lack of ER, PR and HER2 expressions in neoplastic tissue. As regards 
breast cancer, the triple negative phenomenon has been thoroughly investigated. Triple 
negative cancers (TNCs) represent about 10–20% of all breast cancers and lead to worse 
outcomes. The authors of the study cited above suggest a better prognostic value of HER-2 
overexpression than that of PTEN [13].  
  It was not until 2010 that TNP was described in reference to a cancer different than 
breast cancer. It was found that the percentage rate of endometrial TNCs was 26%. They were 
at a more severe clinical stage at the time of diagnosis and were accompanied by the presence 
of lymph node metastases, deeper uterine infiltration and an unfavourable histopathological 
type, i.e., clear-cell or serous carcinoma. There is a limited number of reports of triple 
negative endometrial cancer [14–19].  
 
Objectives 
The purpose of this study was to assess the percentage of endometrial carcinomas with 
TNP and the survival odds for patients with endometrial cancer with TNP. 
 
MATERIAL AND METHODS 
The study group consisted of 265 women with histopathologically confirmed 
diagnosis of endometrial cancer who underwent surgery between 2004 and 2016.  
The patients were divided into two groups: 
1. Patients with endometrial cancer with TNP 
2. Patients with endometrial cancer without TNP 
The observations were terminated on 9 October 2018. On the last day of the 
observation, the total of 53 patients was reported to have died. In 26 cases it was not possible 
 
 
to obtain information concerning the exact date of death. Data on patients' deaths were 
collected from the register of deaths run by Department of State Systems of the Polish 
Ministry of Digitization.  
For the purpose of prognosis assessment, the overall survival (OS) was defined as the 
time from surgery to the end of observation or to the patient's death.  
The research project received a favourable opinion by the Bioethical Commission of 
the Pomeranian Medical University in Szczecin no. KB-0012/01/01/2015 of 07 January 2015. 
The description of the study group is shown in Table 1. 
The study was conducted on tissue microarrays (TMA) made of paraffin blocks 
including material retrieved for the purpose of routine histopathological tests from post-
surgery preparations fixed in 10% formalin solution and embedded in paraffin. TMA is a 
multi-stage technique. First, the representative locations were selected from the original 
histopathological specimen stained with haematoxylin and eosin. There were three 
representative locations of tumour metastasis. In the second stage cylindrical tissue samples of 
0.6 mm in diameter were extracted from the places in the donor paraffin block that correspond 
to the places marked in the histopathological preparation and placed in the pre-drilled 
recipient block. Subsequently, the recipient block was embedded in paraffin. In the final 
stage, the block was cut into 4-µm-thin segments that are subject to immunohistochemical 
examination or to fluorescent in situ hybridization (FISH) [20, 21]. A large number of 
fragments of various preparations in one recipient block formed a map representing a position 
of each preparation. The array of these fragments in the recipient block needed to be precisely 
spaced so that each sample can be unambiguously identifiable. 
In this study the immunohistochemical protocol was used to assess the expression of 
ER and PR. The process of immunohistochemical staining by means of the EnVision™ FLEX 
Dako set consisted of several consecutive stages. First, the slides obtained from the paraffin 
blocks with the microarrayed tissue was deparaffinised for 60 minutes in a dry oven at 58°C. 
Then the antigen was deparaffinized by hydrothermal pressure at 120ºC with the retrieval 
buffer En Vision™Flex Target Retrieval Solution, high pH. Subsequently, the endogenous 
peroxidase was blocked for five minutes by means of En Vision™Flex Peroxidase-Blocking 
Reagent. For another five minutes the slides were immersed in the (En Vision™Flex Wash 
Buffer). In the following stage the slides were incubated with primary antibody. The used 
antibodies were anti-estrogen receptor (clone 1D5, 1:50 solution, Dako) and anti-progesterone 
 
 
receptor (clone PgR 636, 1:50 solution; Dako). The incubation time was 20 minutes. Next, the 
slides were immersed in the buffer for another five minutes followed by 20-minute incubation 
with the polymer (EnVisionTM FLEX /HRP). The last buffer wash took five minutes. Then 
the staining procedure with EnVisionTM FLEX DAB+ Chromogen took place for 10 minutes 
followed by a 10-minute bath in de-ionized water. One of the last stages was the immersion in 
haematoxylin staining (EnVisionTMFLEX Hematoxylin) for another 10 minutes, followed by 
10 minutes of washing the slides in tap water. Finally, the slides were dehydrated by 
immersing the slides in several isopropyl alcohols of strength growing gradually from 70% to 
98% and in several xylene solutions of varying concentration. In the last step, the slide was 
protected with a coverslip and a commercial antifading mountant (Dako Mounting Medium). 
HER-2 expression was tested with HercepTest (Dako). With HER-2 expression value 
at 2+, an additional staining of FISH was performed in order to determine the HER-2 gene 
amplification. FISH is performed in several stages. It starts with cutting the paraffin block 
into 4-5µm thin segments that are mounted on microscope slides. In this study the test was 
performed according to a standard HER-2-dedicated FISH protocol recommended by the 
manufacturer. The LSI HER-2/neu and CEP17 probes from PathVysion HER-2 DNA Probe 
Kit (Abbott Laboratories) were used. Fluorescent in situ hybridisation is a technique where 
tissue is treated with proteolytic enzymes (here: proteinase K) in order to destroy proteins 
constituting the cell membrane. Tissue is covered with the DNA probe solution being a 
mixture of two molecular probes. The HER-2/neu (LSI — Locus Specific Identifier) probe, 
which is rendered orange with fluorochrome, binds to the HER-2 gene sequence while the 
second probe (CEP — Chromosome Enumeration Probe), rendered green, binds to the 
complementary area of chromosome 17 centromer. The samples were then denaturised and 
hybridized. Cell nuclei were identified by means of DAPI stain. The hybridisation effects 
were assessed under the fluorescence microscope. The relation between LSI (HER-2/neu) 
probe and CEP17 probe was quantified by the so called HER2/CEP17 ratio. 
The H-Score is a semi-quantitative method for assessing the intensity of protein or 
receptor expression and the quantity of cells indicating individual degrees of expression. The 
score gives a range from 0 to 300. In case of the H-Score two cut-off values were used based 
on literature data. According to McCarty et al. [22], the ER expression is regarded positive 
when the H-Score is equal to and higher than 75. McCarty et al., criteria were also used by 
other authors [23]. However, according to Thinke et al. [24], the H-Score below 50 is 
considered negative for ER or PR expression. It is noteworthy that a threshold below 75 was 
 
 
described in the studies on breast cancer and endometrial cancer, as opposed to a threshold 
below 50 which was described solely for breast cancer [22–24]. Therefore, two cut-off values 
of the negative ER and PR expression were adopted for the H-Score: below 50 and below 75. 
The eight-grade score by Allred et al., was also used to identify ER and PR 
expressions [25]. The score from 0 to 6 was used to describe the proportion of tumour cells 
showing positive nuclear staining — A (0 = none; 1 ≤ 1%; 2 = 2–9%; 3 = 10–33%; 4 = 34–
66%; 5 > 66%) while the score from 0–4 represented the staining intensity — B (0 = none; 1 
= weak; 2 = moderate; 3 = strong). The result was described as the sum of A + B = TS (Total 
Score). The original system used by Allred distinguished two categories: no expression when 
TS equalled 0–2 points, and positive expression at TS between 3–8 points. Regarding 
endometrial cancer, Gottwald et al., used modified TS scales for the Allred score. They 
assumed that for a score of 0 points — no expression was found; at 2–4 points the expression 
was considered weak, while at 5–8 points the expression was seen as strong [26]. Given the 
literature data on the percentage of endometrial cancers showing TNP, the following 
interpretation was adopted for the purpose of this study: the number of points equal to or 
below 4 — no expression of ER and PR, while the points above 4 — a positive expression.  
The HER2 expression was interpreted according to standard criteria. In the absence of 
recommendations concerning HER2 determination in endometrial cancers, the 
recommendations for interpreting HER2 test results for breast carcinomas were followed [27]. 
In cases of doubt (HER-2 was at the level of 2+), FISH was performed with the purpose of 
determining the number of gene copies. Depending on the scale used to assess PR and ER 
expression, the criteria outlined in Table 2 were adopted for diagnosing the triple negative 
phenomenon. 
The tissue microarray preparation was scanned with Aperio Cs scanner. The 
proportion of cells showing a positive response was evaluated using computer image analysis 
by means of the Nuclear Image Analysis virtual microscopy system. The process was made 
possible due to the application of algorithms (Image Score Version 11.2.0.780) evaluating the 
intensity of immunohistochemical reactions and their number. The evaluation of HER2 
expressions was done manually. 
The normality of distributions of all variables was checked by Kolmogorov-Smirnov 
test. The statistical relationships between discontinuous variables were examined using 
Pearson's χ2 test. The survival analysis was employed to assess the overall survival. The 
 
 
results were presented with Kaplan-Meier curves. In order to decide which factors increased 
the survival odds, the Cox regression model was used. The results were described with HR 
(Hazard Ratio) with 95% confidence interval and probability. The differences were 
considered statistically significant when their probability was lower than 0.05. 
 
RESULTS 
Depending on the score system used, TNP was found in 10.19–15.09% of cases. The 
results are listed in Table 3. Depending on the criteria adopted for the diagnosis, the 
proportion of deaths varied from 25.71% to 29.17% of patients with TNC. Although there 
were discrepancies in the death rates of patients with and without TNP, no statistically 
significant differences were found. The proportions of deaths by the criteria adopted for the 
TNP diagnosis are outlined in Table 4. In the next stage of the study, the analysis of survival 
was performed using Kaplan-Meier curves in relation to the TNP incidence, depending on the 
applied diagnosis criterion. Further analysis by the Cox regression method failed to provide 
the answer whether TNP was or was not a risk factor leading to the death of patients, 
regardless of the adopted diagnostic scoring system. The results are given in Table 5. The 
presence of TNP, irrespective of the criteria applied in endometrial cancer, was neither a 
factor increasing the risk of death nor it affected the patients' survival. 
 
DISCUSSION 
The studies describing TNP in endometrial cancer are scarce. Three research teams 
adopted the following criteria for determining the ER and PR status: the expression at the 
level 3+ was assumed to be the strong or weak expression of 50% or more of all cells, while 
the expression at the level 2+ was assumed to be the strong or weak expression in the range of 
≥ 50% and ≤ 10% of all cells. The results classified as 1+ or 0 were considered negative, 
whereas 1+ meant strong or weak expression of less than10% of all cells. The absence of 
receptor expression was defined as 0 [14, 16, 18]. It should be noted that the results of the 
presented score differ greatly when converted to the H-Score. Basing on the assumption that 
the result of below 10% of cells with positive weak or strong expression converted to the H-
Score was between 10 and 30 and that all other cells did not show any expression, Voss et al. 
maintained that a H-Score below 150 translated to negative ER or PR expression [15]. 
 
 
In all the existing publications on endometrial cancer with TNP, the criteria for 
determining the HER2 receptor status were based on the standard adopted for breast cancer 
[27]. 
In this paper different criteria were adopted for the identification of a negative status 
of steroid receptors. Two scoring systems were used: H-Score and Allred score. 
The Allred score is generally employed to determine the status of steroid receptors in 
order to diagnose the triple negative breast cancer [28]. It seemed, therefore, appropriate to 
examine the criteria for diagnosing TNP in breast cancer in reference to endometrial cancer. 
The H-Score was the most accurate scoring system for evaluating PR and ER 
expressions in digital image analysis which allowed for precise determination of the 
percentage of cells showing particular degrees of receptor expression. In this study a decision 
was made to adopt two thresholds when classifying expressions of steroid receptors by means 
of the H-Score. The cut-off threshold of < 75 stemmed from including all cases considered 
negative [22]. The cut-off threshold of < 50 resulted from the assumption that the group was 
composed exclusively of the cases with negative status of steroid receptors [24]. It is worth 
noting that the above-mentioned criteria were applied to endometrial and breast cancer in the 
former case, while in the latter case — only to breast cancer [22–24]. 
 When calculated according to the criteria quoted in the literature, the percentage of 
cancers with TNP ranged from 12% to 26%. The discrepancies in results may have been 
caused by specific characteristics of the examined populations. Each study was conducted on 
a different continent. In a study covering the European population, the percentage of 
endometrial cancers with TNP was 12% [18]. In one publication, the percentage of 
endometrial cancers showing TNP was not determined [15]. In the present study the 
percentage of triple negative cancers ranged from 10.19% to 15.09%. When adopting the 
criteria of diagnosis according to the Allrad score, the proportion of TNP was 10.19%. In the 
case of the H-Score < 50 it reached 10.94%, while according to the H-Score < 75 it was even 
higher at 15.09%. If the criteria used most often in the literature were adopted, in the 
population under study the percentage of endometrial cancers with TNP would range between 
5.24 and 8.61% [14, 16, 18]. When adopting the TNP diagnosis criteria proposed by Voss et 
al., the percentage of triple negative endometrial cancers would amount to 37.09%. In view of 
vast discrepancies among the above outcomes, it is necessary to adopt unified criteria for the 
diagnosis of TNP, as in the case of triple negative breast cancer. 
 
 
 Breast cancer with TNP is burdened with poor prognosis [29]. Similar observations 
were made for triple negative ovarian cancer [30]. This type of cancer occurs more frequently 
in young patients and is characterized by an aggressive course. The present study found that 
the incidence of TNP was correlated with older age of patients at the time of diagnosis. Data 
concerning the age of patients diagnosed with endometrial cancer with TNP are contradictory. 
The results of one study turned out to be consistent with the results of the present 
study, while other authors did not show such a correlation [16, 18]. However, those authors 
revealed the relationship between poorer survivals of patients with TNP endometrial cancers. 
This relationship was not confirmed in this study, irrespective of the criteria used to diagnose 
TNP. It should be noted that shorter survival was correlated with the presence of TNP, 
regardless of the organ affected by the disease. It is worth noting, however, that the number of 
publications on survival in tumours of organs other than breast cancer is limited. 
 In this study, the system of digital image analysis was used to analyse the degree of 
expression of individual receptors, with the exception of the HER-2 receptor expression 
which was assessed manually according to the applicable criteria [27]. Significant subjectivity 
was observed in the assessment of receptor expression in the same histopathological 
preparation performed by several pathologists. In order to eliminate the above problem, 
programmes to count cells showing a positive response to the immunohistochemical staining 
reaction were developed. Endometrial cancer research has already used digital image analysis 
before [31, 32]. For years numerous research teams have studied the variables relating to the 
morphology of cell nuclei in endometrial cancer [32, 33]. Paulik et al. [34], used digital image 




The following conclusions were reached when verifying the research hypotheses put 
forward for the purpose of this study: 
1. The percentage of TNP diagnosed in endometrial cancer depends on the population 
tested and the criteria adopted.  
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Table 1. Study group description 
 
Parameters under evaluation  N Number % 




SD 9.73 – 
Median 62 – 





Mucosal carcinoma 0 0 
Serous carcinoma  4 1.51 
Clear-cell carcinoma  3 1.13 









G2 92 34.72 
G3 29 10.94 




IB 68 25.66 
II 24 9.06 
 
 
SD — standard deviation; FIGO — International Federation of Gynecology and Obstetrics; 




Table 2. Criteria for TNP diagnosis 
TNC — triple negative cancer; PR — progesterone receptor; ER — estrogen receptor  
 

















IIIA 15 5.66 
IIIB 0 0 
IIIC 1 1 0.38 
IIIC 2 0 0 
IVA 1 0.38 
IVB 1 0.38 
BMI 
< 25,0 normal weight 
240 
47 19.58 
(25–29.99) overweight 71 29.58 
(30–34,99) 10 obesity 68 28.33 
(35–39,99) 20 obesity  34 14.17 





Present 160 62.5 









Criteria for TNC diagnosis 
H-Score ≤ 50 PR and ER ≤ 50 by H-Score and rec. HER – 2 negative 
H-Score ≤ 75 PR and ER ≤ 75 by H-Score and rec. HER – 2 negative 
Allred  ≤ 4 PR and ER ≤ 4 by Allreda and rec. HER – 2 negative 
 
Number % 
TNC at H-SCORE < 75   
Absent 225 84.91 
Present 40 15.09 
TNC at H-SCORE < 50   
Absent 236 89.06 
Present 29 10.94 
TNC at Allred Score    
Absent 238 89.81 
Present 27 10.19 
 
 
Table 4. Comparison of mortality rate by incidence of TNP and score type 
TNP — triple negative phenomenon 
 
Table 5. TNP – death risk factor – Cox regression analysis 
Risk factors HZ 95%  CI p 
Incidence of TNP by H-Score < 75 1.10 0.54 2.27 0.787 
Incidence of TNP by H-Score < 50 1.27 0.57 2.82 0.561 
Incidence of TNP by Allred Score 1.09 0.47 2.57 0.836 








Endometrial carcinoma (whole population under study) 
 
Death – Death + p 
TNP by H-Score < 75            
Absent 160 78.43% 44 21.57% 0.58545 
Present 26 74.29% 9 25.71%   
TNP by H-Score < 50           
absent  169 78.60% 46 21.40% 0.38474 
present 17 70.83% 7 29.17%   
TNP by Allred Score           
absent 169 78.24% 47 21.76% 0.63482 
present 17 73.91% 6 26.09%   
 
 
 
 
 
 
 
  
